Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.
Interferon-alpha (IFN-alpha) treatment is frequently complicated by symptoms of depression. The mechanism by which peripherally administered IFN-alpha enters and modulates the central nervous system remains unclear. The cell adhesion molecule ICAM-1 is involved in the regulation of blood-brain barrier (BBB) permeability. ICAM-1 expression was shown to increase during IFN-alpha treatment and recently the expression of ICAM-1 on vascular endothelial cells in the brain was found to be correlated with the development of depression. We therefore hypothesized that soluble ICAM-1 may be involved in the development of IFN-alpha associated depression. In a prospective study, serum levels of soluble ICAM-1 (double sandwich ELISA test) and symptoms of depression (SDS) were measured in 48 patients with malignant melanoma before and during adjuvant IFN-alpha treatment. Both, depression scores and the serum levels of sICAM-1 significantly increased after three months of IFN-alpha treatment compared to baseline levels (p < .001). Patients who developed depression (SDS-index scores > or = 50) after three months of treatment had higher sICAM-1 levels compared to non-depressed patients. Furthermore, sICAM-1 levels were positively correlated with SDS values (r = .367, p = .018). Our data provides evidence for an association between the induction of sICAM-1 and the development of symptoms of depression during IFN-alpha treatment, possibly by enhancing BBB-permeability.
Department of Psychiatry, Charité-University Medicine Berlin, Campus Charité Mitte, Schumannstr. 20/21, D-10117 Berlin, Germany. martin.schaefer@charite.de
Martin
M
Schaefer
Martin
M
Horn
Folkhard
F
Schmidt
Monika H
MH
Schmid-Wendtner
Matthias
M
Volkenandt
Manfred
M
Ackenheil
Norbert
N
Mueller
Markus J
MJ
Schwarz
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D001812:Blood-Brain Barrier / Q000187:drug effects; D003866:Depressive Disorder / Q000097:blood* / Q000139:chemically induced*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood* / Q000187:drug effects; D016898:Interferon-alpha / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D008875:Middle Aged; D009483:Neuropsychological Tests; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000523:psychology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D018799:Intercellular Adhesion Molecule-1